Menu
Not yet recruiting NCT07442071

Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome

Phase III Interventional Out-of-hospital Cardiac Arrest (OHCA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Epinephrine 0.5 mg intravenous bolus, Epinephrine 1 mg intravenous bolus.
Who it may be relevant to
Registry conditions: Out-of-hospital Cardiac Arrest (OHCA). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome: A Multicenter Randomized and Double-blind Trial.

Overview

This study will test whether a lower dose of epinephrine (0.5 mg) given during emergency treatment for out-of-hospital cardiac arrest helps more patients survive with good brain function, compared to the standard dose (1 mg). Adults who experience cardiac arrest outside the hospital and are treated by emergency medical teams will be randomly assigned to receive either the low dose or the standard dose of epinephrine. The study will compare survival and neurological outcomes between the two groups over 28 days.

Interventions

  • Drug Epinephrine 0.5 mg intravenous bolus
    Epinephrine 0.5 mg/mL solution for injection, administered as a 0.5 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest. T
  • Drug Epinephrine 1 mg intravenous bolus
    Epinephrine 1 mg/mL solution for injection, administered as a 1 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest.

Primary outcome measures

  • Modified Rankin Scale (mRS) score [Time frame: 28-day]
Secondary outcome measures (4)
  • Return of Spontaneous Circulation (ROSC). [Time frame: Periprocedural period of cardiopulmonary resuscitation]
  • Vital status [Time frame: Periprocedural period of cardiopulmonary resuscitation]
  • vital status [Time frame: 28 days post-cardiac arrest]
  • Modified Rankin Scale (mRS) score. [Time frame: 28 days post-cardiac arrest]

Eligibility criteria

Inclusion criteria

Male or female, aged ≥18 years. Out-of-hospital cardiac arrest for which resuscitation is decided by the SMUR team.

Medical Out-of-hospital cardiac arrest. Affiliated with or beneficiary of a social security plan

Exclusion criteria

  • Non-medical Out-of-hospital cardiac arrest (traumatic, drownings, electrocution, asphyxia, overdose, unknown cause).
  • Out-of-hospital cardiac arrest without advanced life support (Do Not Attempt Resuscitation order, body finding, the decision not to attempt advanced life support is at the physician's discretion).
  • Pregnant women, birthing or breastfeeding mothers
  • Adults under legal protection measure (such as guardianship, conservatorship)
  • Individuals deprived of liberty due to judicial or administrative decision

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

France · 26 centers
  • CH Annecy — Annecy
  • Centre hospitalier de la Côte Basque — Bayonne
  • CHU Besancon — Besançon
  • CHU Brest — Brest
  • CHU Colmar — Colmar
  • CH SUD Francilien — Corbeil-Essonnes
  • Brigade de Sapeurs-Pompiers de Paris — Courbevoie
  • Centre Hospitalier Universitaire Grenoble Alpes — La Tronche
  • … and 18 more centers

Identifiers

NCT: NCT07442071 · 2021PI170 · 2023-505349-26-00

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗